BioCentury
ARTICLE | Company News

J&J, PharmaMar sales and marketing update

December 21, 2015 8:00 AM UTC

The U.K.’s NICE issued preliminary draft guidance recommending Johnson & Johnson’s Caelyx pegylated liposomal doxorubicin as monotherapy or in combination with platinum to treat recurrent ovarian cancer. The guidance recommends against Caelyx in combination with Yondelis trabectedin from PharmaMar. NICE concluded that the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained for the combination is likely over L77,300 ($117,125). The agency also noted that the combination did not fulfill the criteria for an end-of-life treatment. ...